Open AccessComparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients
Author(s) -
Ajit Avasthi,
Parmanand Kulhara,
Gagandeep Singh,
Rajni Sharma,
Rajinder Kaur
Publication year - 2005
Publication title -
indian journal of psychiatry/indian journal of psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.485
H-Index - 34
eISSN - 1998-3794
pISSN - 0019-5545
DOI - 10.4103/0019-5545.55951
Subject(s) - moclobemide , tolerability , antidepressant , monoamine oxidase a , monoamine oxidase inhibitor , imipramine , psychology , medicine , pharmacology , monoamine oxidase , adverse effect , chemistry , serotonin , biochemistry , receptor , alternative medicine , pathology , hippocampus , enzyme
Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India.